The weight loss itself drives the health benefit, not just the ongoing drug
A large real-world study of nearly 90,000 Americans on GLP-1 medications has confirmed what medicine has long suspected but rarely measured so precisely: the body rewards sustained weight loss with measurably fewer serious illnesses. Led by researchers at the University of Liverpool and drawing on years of electronic health records, the findings — to be presented at the European Congress on Obesity in Istanbul — reveal that patients who lost 15 percent or more of their BMI faced dramatically lower risks of osteoarthritis, kidney disease, sleep apnea, and heart failure. The study also surfaces a quieter truth: half of patients stopped their medication within a year, yet those who had lost weight retained its protective gifts regardless, suggesting that the transformation, not the drug, is the enduring medicine.
- The stakes are concrete: patients losing 15% or more of their BMI saw sleep apnea risk fall by 69% and osteoarthritis risk drop by 37%, while those who gained weight faced a 69% higher risk of heart failure.
- Real-world behavior complicates the picture — half of nearly 90,000 GLP-1 users abandoned treatment within twelve months, exposing a yawning gap between clinical promise and lived adherence.
- The disruption cuts both ways: those who lost the most weight avoided serious chronic disease, while those whose weight increased faced compounding risks across every condition studied.
- A critical finding steadies the alarm: weight loss retained its protective power even after patients stopped taking the drug, shifting the clinical focus from medication continuation to weight maintenance itself.
- The path forward is clear but difficult — researchers and clinicians must now grapple with why so many patients discontinue, whether cost, side effects, or the sheer weight of sustained change is to blame.
A study tracking nearly 90,000 patients who began GLP-1 medications for obesity or diabetes has found that the degree of weight loss — not merely the act of taking the drug — determines how much protection patients gain against serious complications. Led by Professor John Wilding at the University of Liverpool, the research will be presented at the European Congress on Obesity in Istanbul and draws on U.S. electronic health records and insurance claims spanning January 2021 through June 2025.
The cohort included patients on semaglutide, tirzepatide, and liraglutide, with an average age of 57 and a starting BMI of 34.7. Roughly six in ten had type 2 diabetes. Researchers sorted patients by how much BMI they lost in their first year of treatment, then followed them for nearly a year more to track who developed osteoarthritis, chronic kidney disease, obstructive sleep apnea, or heart failure.
The results were dose-dependent and striking. Those who lost 15 percent or more of their BMI saw osteoarthritis risk fall 37 percent, chronic kidney disease risk drop 30 percent, sleep apnea risk plummet 69 percent, and heart failure risk decline 32 percent — all compared to patients who lost less than 5 percent. Even modest losses of 5 to 10 percent offered meaningful protection. Patients whose weight increased fared worst, facing a 69 percent higher risk of heart failure than the minimal-loss group.
Perhaps the study's most consequential finding is that the protective effect of weight loss persisted even among the half of patients who stopped their medication within a year. This suggests the body's response to weight loss is durable — that the transformation itself, once achieved, carries forward. The challenge the data quietly names is adherence: why so many patients discontinue, and what it would take to help more of them stay the course long enough to reap the benefit.
A large real-world study tracking nearly 90,000 patients who started GLP-1 drugs for obesity or diabetes found something straightforward but important: the more weight people lost, the less likely they were to develop serious health complications down the road. The research, led by Professor John Wilding at the University of Liverpool, will be presented this month at the European Congress on Obesity in Istanbul and offers a window into how these medications actually perform outside the controlled environment of clinical trials.
The drugs in question—semaglutide, liraglutide, and tirzepatide—have become fixtures in obesity treatment and diabetes management. Randomized trials have shown they work. But real life is messier. Half the patients in this study stopped taking their medication within a year, and the amount of weight people lost varied wildly. The researchers wanted to know whether that variation mattered for actual health outcomes. Using electronic health records and insurance claims data from the United States spanning January 2021 through June 2025, they tracked what happened to patients in the year after they started treatment, then followed them for another eleven months to see who developed complications.
The cohort was substantial: 67,841 patients on semaglutide, 15,661 on tirzepatide, and 6,216 on liraglutide. At the start, the average patient was 57 years old with a BMI of 34.7, and about six in ten had type 2 diabetes. The researchers measured how much each person's BMI changed in that first year and sorted them into groups: those who lost less than 5 percent, those who lost 5 to 10 percent, those who lost 10 to 15 percent, and those who lost 15 percent or more. They also tracked patients whose weight actually increased. Then they watched to see who developed osteoarthritis, chronic kidney disease, obstructive sleep apnea, or heart failure.
The numbers told a clear story. Patients who achieved a 15 percent or greater BMI reduction had substantially lower odds of developing these conditions compared to those who lost less than 5 percent. Osteoarthritis risk dropped 37 percent. Chronic kidney disease risk fell 30 percent. Obstructive sleep apnea risk plummeted 69 percent. Heart failure risk declined 32 percent. Even patients who lost a modest amount—5 to 10 percent—saw meaningful protection. On the flip side, patients whose weight increased faced worse odds across the board. Those with higher BMI had a 22 percent increased risk of sleep apnea and a striking 69 percent higher risk of heart failure compared to the minimal-loss group.
What makes this study particularly relevant is that it captures real behavior, not the idealized adherence of a trial. Half the patients stopped taking their medication within twelve months, yet the protective effect of weight loss persisted regardless of whether they continued treatment or not. This suggests that the weight loss itself—not just the ongoing presence of the drug—drives the health benefit. The incidence rates for complications were substantial: over an eleven-month follow-up period, there were 21.4 cases of osteoarthritis per 1,000 person-years, 21.1 cases of chronic kidney disease, 20.3 cases of sleep apnea, and 3.9 cases of heart failure.
The researchers conclude that achieving and maintaining weight loss after starting GLP-1 treatment is clinically critical. The challenge, evident in their data, is that half of patients discontinue therapy within a year. Whether that discontinuation reflects side effects, cost, or simply the difficulty of sustained behavior change remains an open question. But the message is clear: for patients who do stick with treatment and lose significant weight, the payoff in terms of avoided complications is substantial.
Citas Notables
Not losing weight was associated with worse clinical outcomes while larger reductions were associated with decreased risks. These findings highlight the potential clinical importance of achieving and maintaining weight loss after GLP-1-based treatment initiation.— Professor John Wilding, University of Liverpool
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that half the patients stopped taking the drug? Couldn't that muddy the findings?
Actually, it sharpens them. The study tracked weight loss itself, not medication adherence. So even patients who quit still benefited from the weight they'd already lost. That's clinically important—it means the protection isn't dependent on staying on the drug forever.
But doesn't that seem odd? Usually we think of medications as needing continuous use to work.
These drugs work by helping you lose weight. Once that weight is gone, your joints, your kidneys, your heart—they're carrying less load. The drug's job is done. The question becomes whether people can keep the weight off without it.
So the real challenge is maintenance, not the initial weight loss.
Exactly. The drugs are effective at creating weight loss. The harder part is what happens after—whether people regain it, whether they restart treatment, whether they've built habits that stick.
The sleep apnea numbers jumped out—69 percent lower risk with 15 percent weight loss. Why such a dramatic difference there?
Sleep apnea is directly mechanical. Extra weight around the neck and throat collapses your airway. Lose that weight, and the obstruction often resolves. It's one of the most responsive conditions to weight loss.
And heart failure? That was also significant in the group that gained weight.
Heart failure is more complex—it involves the whole cardiovascular system. But carrying excess weight strains the heart. The 69 percent increased risk in the weight-gain group suggests that for people already at risk, even modest weight gain can tip them toward serious trouble.
What would you want to know that this study doesn't tell us?
Why half the patients quit. Was it cost? Side effects? Did they feel better and think they didn't need it anymore? Understanding that would help us design better support systems to keep people engaged with treatment.